Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Hønefoss – page 46

606 clinical trials in Hønefoss, Norway. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Hønefoss at a glance
606
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

606 trials in Hønefoss

Open in trial search

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Plasma cell myeloma

Not recruiting

Study of Daratumumab Injection for Patients with High-Risk Smoldering Multiple Myeloma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Janssen Cilag International

Study on Pyridoxine for Patients with Primary Sclerosing Cholangitis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pyridoxine Hydrochloride
  • Sponsor:Oslo University Hospital HF

Multiple sclerosis

Not recruiting

Study on the Safety of Tenofovir Alafenamide and Natalizumab for People with Multiple Sclerosis

Registered drug
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Natalizumab
  • Sponsor:Helse Bergen HF

Study on the Safety and Effectiveness of Tafasitamab and Lenalidomide for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide
  • Sponsor:Incyte Corp.

Study on the Effect of Adding Thoracic Radiotherapy to Durvalumab and Chemotherapy for Patients with Extensive Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Cervix carcinoma

Not recruiting

Study Comparing Tisotumab Vedotin with Chemotherapy for Patients with Recurrent or Metastatic Cervical Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:Seagen Inc.

Pleural mesothelioma

Not recruiting

Study of Volrustomig with Carboplatin and Pemetrexed for Patients with Unresectable Pleural Mesothelioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Endometrial cancer

Not recruiting

Study Comparing Pembrolizumab and Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Renal transplant

Not recruiting

Study on Reducing Tacrolimus in Kidney Transplant Patients with Low Immunological Risk Using Tacrolimus, Mycophenolic Acid, and Prednisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway

Clinical research in Hønefoss

What the registry says about research in the country

01 Musculoskeletal Diseases

In Hønefoss, researchers are evaluating non‑pharmacologic and medication approaches for acute neck pain. The study compares chiropractic spinal manipulative therapy with standard use of NSAIDs to determine which method best reduces pain intensity during the treatment period.

  • Comparative effectiveness of manual therapy versus medication
  • Measurement of pain intensity and functional recovery
  • Patient‑reported outcome measures
  • Safety and feasibility of combined treatment strategies

Findings aim to guide clinicians in selecting optimal first‑line interventions for neck pain, potentially improving recovery speed and patient satisfaction.

02 Bacterial Infections and Mycoses

Clinical investigators are studying patients with suspected community‑acquired sepsis to assess whether a regimen of narrow spectrum β‑lactam antibiotics together with an aminoglycoside is safe and non‑inferior to standard broad spectrum antibiotics. The goal is to refine early treatment choices while minimizing unnecessary broad‑spectrum exposure.

  • Early antibiotic stewardship in severe infections
  • Safety profiling of combination therapy
  • Efficacy comparison with broad‑spectrum regimens
  • Impact on patient outcomes and hospital stay

Results could support more targeted antibiotic use, preserving effectiveness of broad‑spectrum agents and reducing resistance development.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.